Navigation Links
New Nutraceutical That Stabilizes Blood Sugar Naturally is Introduced
Date:9/25/2007

CARMEL, Ind., Sept. 25 /PRNewswire/ -- Diabco Life Sciences, LLC, an Indiana based company, has introduced a new clinically tested nutraceutical product for consumers concerned about the growing health risks associated with diabetes. This new product, Diabatrol, is a nutrient dense, fiber and antioxidant-rich dietary supplement that has been scientifically proven to stabilize blood sugar spiking and reduce insulin resistance, two conditions that most often lead to Type II diabetes.

Diabetes Risk Rising in the U.S.

According to the American Diabetes Association and the Centers for Disease Control and Prevention, Americans are increasingly at risk for diabetes. Currently, an estimated 107 million individuals in the U.S. are at risk of diabetes or pre-diabetes. Diabetes is a complex disease that impacts many vital functions and organs in the human body. Diabetes can cause vascular and nerve damage, heart disease, increased risk for kidney failure, and blindness. Diabetes experts advise that preventative action, early detection and aggressive management of diabetes can greatly improve the chances for a long and healthy life without significant health complications.

Diabatrol's Role in Reducing Risk

By reducing insulin resistance, Diabatrol works to allow the body to properly utilize insulin and stabilize blood glucose imbalances naturally, thereby helping to reduce the health risks associated with diabetes. Diabatrol's active ingredients not only help promote healthy glucose metabolism, but also help reduce oxidative stress and insulin resistance, two key concerns for diabetics and pre-diabetics.

Diabatrol is a nutraceutical with all natural active ingredients, not a prescription pharmaceutical. Diabatrol is a fortified whole grain derivative that provides a broad nutritional approach to diabetes management. All active nutritional components in Diabatrol have been clinically tested and documented to be beneficial for Type II diabetics. Diabatrol is hypoallergenic, gluten free, low glycemic and contains more than 80 natural antioxidants. Packaged in easy to use single-serving packets, Diabatrol provides a proactive nutritional approach to blood glucose management that can be easily incorporated into a total healthy lifestyle and diabetes wellness program.

Clinical testing of Diabatrol's active ingredients yielded the following results: In a 60-day double-blind randomized trial, Type II diabetes test subjects taking Diabatrol realized a 32.9 percent (52 points) reduction in fasting blood glucose levels and an eight percent reduction in LDL (so-called "bad cholesterol") levels. These clinical tests were peer reviewed and published in the Journal of Nutritional Biochemistry and are more fully documented on the Diabco Life Sciences website at http://www.healthydiabetic.com.

The term nutraceuticals refers to foods that have proven medical or health benefits to help mitigate certain diseases. Diabatrol is among the first nutraceuticals that conform to the new guidelines established under the U.S. Dietary Supplements, Health and Education Act (DSHEA), which is overseen by the U.S. Food and Drug Administration. DSHEA was established by the federal government to regulate the nutritional supplements industry and provide consumers with reliable guidelines for evaluating claims made by makers of such products.

About Diabco Life Sciences, LLC

Diabco Life Sciences, LLC (Diabco) was established in 2003 to focus on diabetes and product research. Diabco's mission is to provide effective nutraceutical products for consumers seeking performance-proven natural alternatives to help manage their blood glucose metabolism and to reduce the health risks associated with Type II diabetes and pre-diabetes. Nutraceuticals are nutrient dense functional foods, "medical foods" by definition that have been tested and proven to help mitigate certain health risks. More information about Diabco can be found at http://www.healthydiabetic.com or by writing to Diabco Life Sciences, 484 East Carmel Drive, #204, Carmel, Indiana, 46032.


'/>"/>
SOURCE Diabco Life Sciences, LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Drug stabilizes cancer growth
2. Recommendations for Treatment of Blood Pressue
3. Blood Cells Capable of Regenerating Liver
4. Infant receives first bloodless liver transplant
5. Spouses and other partners lower blood pressure says new research
6. H2O - a cure for low blood pressure
7. Uncontrolled blood pressure
8. Weight and Blood Pressure
9. Grandmother’s diet in pregnancy can affect grandchildren’s blood sugr
10. Early diagnosis for autism from blood tests may be possible
11. Antibiotic from crab blood indentified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Pass, OR (PRWEB) , ... April 29, 2016 , ... ... suggest dinner as the meal to miss. That was among the many new lifestyle ... Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny and ...
(Date:4/29/2016)... ... , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- Dr. Mickey ... -- are proud of the recent release of their 2014 in vitro fertilization success ... published the latest verified data for 375 U.S. member clinics. *Preliminary data shows HRC/OC ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in ... efficacy of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The ... adding BC and AD, saying it is time to set the record straight. Traditionally, ... says this simply cannot possibly be true and offers explanation. , “To start with, ...
(Date:4/28/2016)... ... April 29, 2016 , ... Sublime Beauty® is offering a special deal on its webstore. ... off. The discount is applied to the product with lesser value. In addition, a ... purchase $250 or more in products. , "So many women (men, too) love our products ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Oasmia Pharmaceutical ... of a new generation of drugs within human ... results for Paclical/Apealea in the Phase III study ... epithelial ovarian cancer. These preliminary results showed non-inferiority ... with carboplatin versus Taxol in combination with carboplatin. ...
(Date:4/27/2016)... At the Sachs CEO forum ... Phase 2 clinical study of its lead drug candidate, ... implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 ... and France . STR001 ... time of surgery. "Despite advances in cochlear implant technology, ...
(Date:4/26/2016)... 2016 US demand for infection prevention ... percent annually to $27.6 billion in 2020.  Increasing ... decrease rates of healthcare-associated infections (HAIs) will boost ... services.  Although declining, the overall rate of certain ... set by the CDC.  Recent statistics indicate that ...
Breaking Medicine Technology: